Provita Poliklinika
- Address
- ul. Baboszewska 1 2U4, 02-647 Warsaw, Poland
Provita Poliklinika - Dermatology Research Center
Provita Poliklinika is a clinical research facility specializing in dermatological conditions, with particular expertise in complex inflammatory skin disorders. The center contributes to advancing therapeutic options for patients with chronic and debilitating skin diseases through participation in multi-phase clinical trials.
- Hidradenitis suppurativa treatment research and dose-optimization studies
- Phase IIb and Phase III dermatological clinical trials
- Moderate to severe inflammatory skin disease management
The facility demonstrates specialized capabilities in conducting complex trial protocols that involve dose-finding phases and confirmatory efficacy assessments. Their involvement in hidradenitis suppurativa research reflects a commitment to addressing challenging skin conditions that significantly impact patients' quality of life, supporting the development of novel biologic therapies for chronic inflammatory dermatoses.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Provita Poliklinika
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. | Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG | Phase IV | Not Recruiting | Oct 2023 | Mar 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Spesolimab | 1 | Unknown | 2023-10-13 | 2023-10-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.